Literature DB >> 15042618

Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

Kalipso Halkidou1, Luke Gaughan, Susan Cook, Hing Y Leung, David E Neal, Craig N Robson.   

Abstract

BACKGROUND: Histone deacetylase 1 (HDAC1) is a co-repressor involved in differentiation and proliferation control. It is upregulated in malignant compared to benign tissue, and targets a number of transcription factors including p53.
METHODS: By immunohistochemistry, HDAC1 protein expression was investigated in human prostate specimens and the CWR22 mouse xenograft model. Flow cytometry and deconvolution immunofluorescence were also performed.
RESULTS: HDAC1 was upregulated in pre-malignant and malignant lesions, with the highest increase in expression in hormone refractory (HR) cancer. Using the CWR22 xenograft model we showed androgen dependent regulation of HDAC1. HDAC1 overexpression led to a significant increase in proliferation and a shift towards the undifferentiated cytokeratin (CK) profile in a PC3M derivative clone constitutively expressing HDAC1.
CONCLUSION: This study underlines the importance of HDAC1 in cell proliferation and the development of prostate cancer (CaP) and proposes a mechanism for HDAC1 nuclear recruitment. HDAC1 may constitute a crucial therapeutic target particularly in the most lethal phase of androgen independence. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042618     DOI: 10.1002/pros.20022

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  174 in total

Review 1.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

Review 3.  Multiple roles of class I HDACs in proliferation, differentiation, and development.

Authors:  Nina Reichert; Mohamed-Amin Choukrallah; Patrick Matthias
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

Review 4.  Epigenetic alterations in aging.

Authors:  Susana Gonzalo
Journal:  J Appl Physiol (1985)       Date:  2010-05-06

Review 5.  Discovery and mechanism of natural products as modulators of histone acetylation.

Authors:  Lilibeth A Salvador; Hendrik Luesch
Journal:  Curr Drug Targets       Date:  2012-07       Impact factor: 3.465

6.  Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study.

Authors:  Mitali Pandey; Parminder Kaur; Sanjeev Shukla; Ata Abbas; Pingfu Fu; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

Review 7.  Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.

Authors:  Besma Abbaoui; Christopher R Lucas; Ken M Riedl; Steven K Clinton; Amir Mortazavi
Journal:  Mol Nutr Food Res       Date:  2018-08-29       Impact factor: 5.914

8.  HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.

Authors:  Corrado Caslini; Sunhwa Hong; Yuguang J Ban; Xi S Chen; Tan A Ince
Journal:  Oncogene       Date:  2019-08-02       Impact factor: 9.867

9.  Role for histone deacetylase 1 in human tumor cell proliferation.

Authors:  Silvia Senese; Katrin Zaragoza; Simone Minardi; Ivan Muradore; Simona Ronzoni; Alfonso Passafaro; Loris Bernard; Giulio F Draetta; Myriam Alcalay; Christian Seiser; Susanna Chiocca
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

10.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.